Cancer Research PRL Inhibitor Induces the Cleavage of p130Cas  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 112-119, January 1, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z. J.
Right arrow Articles by Ferrone, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z. J.
Right arrow Articles by Ferrone, S.

Modulation by Adjuvants and Carriers of the Immunogenicity in Xenogeneic Hosts of Mouse Anti-idiotypic Monoclonal Antibody MK2-23, an Internal Image of Human High Molecular Weight-Melanoma Associated Antigen1

Zhi Jian Chen, Hong Yang, Chang Chin Liu, Shunji Hirai and Soldano Ferrone2

Department of Microbiology and Immunology, New York Medical College, Valhalla, New York 10595

The mouse anti-idiotypic monoclonal antibody (mAb) MK2-23 recognizes an idiotope in the antigen-combining site of the immunizing antihuman high-molecular-weight melanoma-associated antigen (HMW-MAA) mAb 763.74. Administration with an adjuvant of mAb MK2-23 conjugated to a carrier has been shown to induce anti-HMW-MAA antibodies both in syngeneic hosts and in patients with malignant melanoma. Adjuvant and carrier are required for the induction of anti-HMW-MAA immunity in BALB/c mice immunized with mAb MK2-23. Whether both adjuvant and carrier are required also in patients with malignant melanoma is not known and cannot be deduced from results obtained in a syngeneic animal model system. Therefore the present study has evaluated for the first time the effect of a carrier and an adjuvant on the immunogenicity of mAb MK2-23 in a xenogeneic host. Rabbits were selected for this purpose, since they have a constitutive expression of HMW-MAA in their normal tissues with a distribution similar to that in humans. The combined use of an adjuvant and a carrier enhances the immunogenicity of mAb MK2-23 in rabbits markedly more than each of them individually. Specifically, all the rabbits immunized with mAb MK2-23 conjugated to keyhole limpet hemocyanin (KLH) and mixed with Freund's adjuvant (FA) produced antibodies which were shown with serological and immunochemical assays to be specific for HMW-MAA and to be both IgG and IgM. In contrast anti-HMW-MAA antibodies were detected in only one of the 3 rabbits immunized with mAb MK2-23 mixed with FA and were not detected in the rabbits immunized with mAb MK2-23 conjugated to KLH or with mAb MK2-23 without KLH and FA. These results indicate that active specific immunotherapy with mAb MK2-23 in patients with malignant melanoma is likely to benefit from the use of a carrier and an adjuvant, provide additional evidence that mAb MK2-23 bears the internal image of HMW-MAA, and suggest that the immune response elicited by mAb MK2-23 is T-cell dependent.

1 Supported by USPHS Grants CA37959 and CA51814 awarded by the National Cancer Institute, Department of Health and Human Services and by Grant IM-500 awarded by the American Cancer Society.

2 To whom requests for reprints should be addressed.

Received 6/ 8/92. Accepted 10/15/92.




This article has been cited by other articles:


Home page
J. Immunol.Home page
W. Luo, E. Ko, J. C.-f. Hsu, X. Wang, and S. Ferrone
Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects
J. Immunol., May 15, 2006; 176(10): 6046 - 6054.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Peng, E. Ko, W. Luo, X. Wang, P. A. Shrikant, and S. Ferrone
CD4-Dependent Potentiation of a High Molecular Weight-Melanoma-Associated Antigen-Specific CTL Response Elicited in HLA-A2/Kb Transgenic Mice
J. Immunol., February 15, 2006; 176(4): 2307 - 2315.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-C. Chang, F. G. Hernandez-Guzman, W. Luo, X. Wang, S. Ferrone, and D. Ghosh
Structural Basis of Antigen Mimicry in a Clinically Relevant Melanoma Antigen System
J. Biol. Chem., December 16, 2005; 280(50): 41546 - 41552.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Wang, E. C. Ko, L. Peng, S. D. Gillies, and S. Ferrone
Human High Molecular Weight Melanoma-Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Enhancement of Immunogenicity of Anti-Idiotypic Monoclonal Antibody MK2-23 by Fusion with Interleukin 2
Cancer Res., August 1, 2005; 65(15): 6976 - 6983.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. Luo, J. C.-f. Hsu, C.-Y. Tsao, E. Ko, X. Wang, and S. Ferrone
Differential Immunogenicity of Two Peptides Isolated by High Molecular Weight-Melanoma-Associated Antigen-Specific Monoclonal Antibodies with Different Affinities
J. Immunol., June 1, 2005; 174(11): 7104 - 7110.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.